The Cancer Letter, Vol. 19 No. 2: ‘Taxol Approved By FDA For Ovarian Cancer; Bristol Sets Price Tier In Line With Platinum’ (1993)

News Report · The Cancer Letter (Kirsten Boyd Goldberg, ed.) · January 8, 1993

The Cancer Letter (Kirsten Boyd Goldberg, 1993-01-08: Trade report in the January 1993 issue on the FDA approval of Taxol for ovarian cancer, recording Bristol-Myers Squibb's launch prices: $695.25 average per cycle, $986.18 wholesale per cycle, and $146.10 per 30 mg vial.

At the highest level of the pricing tier, the wholesale list price, a cycle of taxol will cost $986.18.

p. 2

The Cancer Letter (Kirsten Boyd Goldberg, 1993-01-08: Trade report in the January 1993 issue on the FDA approval of Taxol for ovarian cancer, recording Bristol-Myers Squibb's launch prices: $695.25 average per cycle, $986.18 wholesale per cycle, and $146.10 per 30 mg vial. Funder/conflicts: independent subscription trade publication; no industry funding disclosed on the page. Maker: Bristol-Myers Squibb (prices announced by the company; Stephen Carter quoted). Comparator: priced 'in line with cisplatin'. This is the best primary-adjacent price record found for launch; it does not support a $20,000-per-cycle figure at any point near launch. Later price escalation is a separate question and is not documented here. Study type: news.